Replies to post #35217 on OncoSec Medical Inc (ONCSQ)

[NY1972]

If IT IL12 dosing has no serious issue, why it is not used on any palpable cancers all these years? May be biotechs/pharmas havn't figured out how to make big bucks with it. NVS rather paid $200 mil for something similar.

Aduro to Receive $200M Upfront, Equity Stake and Future Potential Milestones Collectively Totaling up to $750M, Plus Profit Sharing in the Collaboration


BERKELEY, Calif.--(BUSINESS WIRE)--Aduro Biotech, Inc. today announced the establishment of a major collaboration with Novartis for the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro’s cyclic dinucleotide (CDN) approach to target the STING (Stimulator of Interferon Genes) receptor, that, when activated, is known to initiate broad innate and adaptive tumor-specific immune responses.